Abstract
BackgroundThe important immune checkpoint inhibitors (ICIs), e.g. PD1/PD-L1 and CD47/SIRPα blockers, have yet to be successful for the majority of non-Hodgkin’s lymphoma (NHL), albeit efficacious in NK/T-cell and Hodgkin's lymphoma,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
